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INTRODUCTION
The worldwide spread of carbapenem-resistant Klebsiella 
pneumoniae (KPC-Kp) is a current health threat world-
wide. The first Kpc-Kp was identified in 1993 (Naas and 
Nordmann, 1994). Since then, a large variety of carbapen-
emases have been identified in Enterobacteriaceae.  KPC-
Kp mortality infections range from 18 to 48% (Morrill et 
al., 2015), up to 51-65% in bloodstream infections, depend-
ing on the type of therapy administered (mono vs com-
bo), co-morbidities and risk-factors (Giacobbe et al., 2015; 
Fraenkel-Wandel et al., 2016). This result may be due to 
delayed time to active therapy, pharmacologic limitations 
of available treatment options, and the fact that patients 
with KPC-Kp infections tend to be critically ill (Morrill et 
al., 2015). Patients with hematologic malignancies and 
hematopoietic stem cell transplant recipients are more 
vulnerable to carbapenemase-resistant Enterobacteriaceae 
(CRE) because of chemotherapy-induced gastrointestinal 
mucositis, prolonged hospitalizations and neutropenia, 
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and frequent use of broad-spectrum antibacterial agents 
(Satlin et al., 2014). The mortality of patients submitted to 
BMT and sepsis due to KPC-Kp might be as high as 85% 
(Girmenia et al., 2015a). We decided to treat hematologic 
patients gut colonized by KPC-Kp using oral gentamicin 
regimen of 80 mg four times a day because of the high-
er gentamicin susceptibility rate reported in Italy than in 
other countries (Satlin et al., 2014) and the few contrain-
dications to using oral gentamicin for gut decolonization. 
In fact, this therapeutic regimen may be ideal for this use 
because of the rapid bactericidal activity in vitro against 
gentamicin-susceptible KPC-Kp strain, the virtual absence 
of systemic activity and systemic toxicity when adminis-
tered orally, the low activity on the gastrointestinal flora, 
especially anaerobes (Qureshi et al., 2012; Zuckerman et 
al., 2010; Oren et al., 2014; Saidel-Odes et al., 2011; Tascini 
et al., 2014).
The aim of our study was to test the efficacy of oral gen-
tamicin in gut decontamination from KPC-Kp in hema-
tologic patients, in view of immunosuppressive therapy, 
stem cell transplantation or to prevent sepsis after che-
motherapy.
MATERIALS AND METHODS
We performed a prospective study in a hematologic ward 
of an Italian second level hospital to quantify the efficacy 
of gentamicin gut decontamination from KPC-Kp in he-
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SUMMARY
The mortality for carbapenem-resistant Klebsiella pneumoniae (KPC-Kp) infection ranges from 18 to 48% 
depending on the type of therapy. Mortality rates in hematologic patients are even higher, up to 85%. Gut 
decontamination with oral gentamicin might be an option to avoid a subsequent KPC-Kp infection in 
colonized patients. 
We treated 14 hematologic patients with oral gentamicin, 80 mg four times daily, for 7 to 25 days in order 
to eradicate KPC-Kp from the gut, starting oral gentamicin therapy when possible after the discontinua-
tion of systemic antibiotic therapy.
The overall decontamination rate in the entire study population was 71% (10/14). Out of the 4 patients 
who did not respond to oral gentamicin therapy, 1 KPC-Kp strain was gentamicin resistant and 4 patients 
received concomitant systemic antibiotic therapy (CSAT). One of these patients died from KPC-Kp sepsis. 
The decontamination rate was 90% (9/10) in patients receiving oral gentamicin only, versus 25% (1/4) in 
those also treated with CSAT. No new gentamicin-resistant KPC-Kp strain was isolated during oral gen-
tamicin therapy
Oral gentamicin might be useful for gut decontamination and prevention of KPC-Kp infection. This op-
tion should be considered in patients colonized by a gentamicin-susceptible KPC-Kp strain and not re-
ceiving CSAT.
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matologic patients with and without concomitant infec-
tion. We considered eligible all patients with rectal swab 
cultures positive for KPC-Kp with hematologic disease. 
Our first end-point was the proved gut decontamination.
Rectal swab cultures were performed at the time of hos-
pital admission and every 3 days thereafter. The direct 
rectal swab cultures on chromogen medium for all car-
bapenemase-producing Enterobacteriacae (chromID 
CARBA SMART, bioMerieux, Marcy-l’Etoile, France) was 
used to identify patients with KPC-Kp gut colonization, 
then confirmed by the validated direct screening method 
using boronic acid (Giani et al., 2011). KPC-Kp stool iso-
lates were identified by matrix-assisted laser desorption 
ionization-time of flight (MALDI-TOF) mass spectrometry 
(Vitek MS, bioMérieux). Antimicrobial susceptibility test-
ing was performed using an automated system (VITEK2, 
bioMerieux) and susceptibility was also determined using 
a disk diffusion method according to EUCAST version 3.1 
guidelines, and MICs of gentamicin were confirmed with 
E-test, according to the manufacturer’s instructions (AB 
Biodisk, Solna, Sweden). Interpretation of susceptibility 
data was according to EUCAST breakpoints (version 3.1) 
(EUCAST site). If there was a discrepancy between the au-
tomated system and E-test, the E-test values were chosen 
(Arena et al., 2014).
Patients who met the inclusion criteria were administered 
oral gentamicin (80 mg 4 times daily) for 7 to 25 days, hav-
ing stopped the therapy 3 days after the proved decontam-
ination. Decontamination was defined as 2 rectal swabs, 
taken at least 48 hours apart, negative for KPC-Kp. The 
follow-up period was 3 months. All patients provided writ-
ten informed consent to participate to the study.
RESULTS
Fourteen patients with a hematologic disease and con-
comitant KPC-Kp positive rectal swab cultures were en-
rolled in the study. The patients were 5 females and 9 
males, with a mean age of 68.5 years (range 39-80 years). 
Their underlying diseases were: acute myeloid leukemia (4 
pts), non-Hodgkin’s lymphoma (3 pts), multiple myeloma 
(2 pts), Hodgkin’s lymphoma (1 pt), chronic lymphocytic 
leukemia (1 pt), myeloproliferative disorders (1 pt), myelo-
dysplastic syndrome (1 pt) and Waldenstrom’s macroglob-
ulinemia (1 pt). Out of 14 KPC-Kp isolated, only 1 was re-
sistant to gentamicin (MIC >16 mg/L), but we treated him 
because of the high gentamicin concentration reached in 
the gut and the importance of decolonization in this case. 
Two other strains had MIC of 4 mg/L at automated system 
but it was 2 mg/L when tested with E-test, therefore ful-
ly susceptible. All strains were resistant to carbapenems; 
2/14 were resistant to colistin; 6/14 were resistant to fosfo-
mycin; 2/14 resistant to tigecycline. Concomitant systemic 
associated therapy (CSAT) was administered to 4/14 pa-
tients (2 with carbapenem) due to infected surgical wound 
(2/4), urinary tract infection (1/4) and pneumonia (1/4). 
Only 2/14 patients were treated with meropenem before 
KPC-Kp gut colonization, for other infections.
The enrolled patients were treated with oral gentamicin 
for 7 to 25 days and the overall decontamination rate in 
the entire study population administered oral gentamicin 
was 71% (10/14). Four patients were not decolonized by 
gentamicin oral therapy: 1 of these was the patient har-
bouring gentamicin-resistant strain and 3 patients had 
CSAT (2/3 with carbapenem). One out of these 4 patients 
died from KPC-Kp sepsis. At 3 months of follow-up from 
the proved decolonization, no KPC-Kp re-colonization was 
documented. The decontamination rate was 90% (9/10) in 
patients receiving oral gentamicin only, versus 25% (1/4) 
in those also treated with CSAT. No new gentamicin-resis-
tant KPC-Kp strain was isolated during oral gentamicin 
therapy (Table 1).
DISCUSSION
KPC-Kp infections are associated with high mortality and 
morbidity, especially in Intensive Care Units and hema-
tologic patients (Girmenia et al., 2015b). Patients with 
Table 1
Pt Age Previous Antibiotic therapy (30 days before)
Kp-KPC Gentamicin 
MIC (mg/L)
Gentamicin
duration therapy CSAT Decolonization
Death due 
to Kp-KPC sepsis
1 74 ciprifloxacin, daptomycin 0.75 14 fosfomycin no no
2 65 daptomycin, rifampicin, 1 7 daptomycin yes no
3 71 piperacillin/tazobactam, 
teicoplanin
2 14 none yes no
4 39 levofloxacin >16 14 none no no
5 62 piperacillin/tazobactam, 
teicoplanin, meropenem
2 13 meropenem no no
6 63 piperacillin/tazobactam, 
teicoplanin, meropenem
2 11 meropenem no yes
7 72 none 1 8 none yes no
8 72 piperacillin/tazobactam 1 8 none yes no
9 79 ceftriaxone 0.75 7 none yes no
10 74 cotrimoxazole 1.5 7 none yes no
11 72 none S 11 none yes no
12 77 none S 12 none yes no
13 59 cotrimoxazole S 10 none yes no
14 80 doxiciline S 25 none yes no
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hematology malignancies and hematopoietic stem cell 
transplant recipients may have a worse outcome in case 
of KPC-Kp infections, with a higher incidence of infec-
tion because of chemotherapy-induced gastrointestinal 
mucositis and neutropenia, prolonged hospitalizations 
and frequent use of broad-spectrum antibacterial agents. 
Therefore, infections caused by KPC-Kp are extremely 
worrisome and the mortality rates may be as high as 80% 
(Girmenia et al., 2015a). An appropriate CRE-targeted 
antibiotic therapy (CTAT) was defined as a combination 
including at least two among colistin/polymyxin B, tige-
cycline and gentamicin, preferably with the addition of 
meropenem, and eventually fosfomycin (Averbuch et al., 
2013). The GITMO (Gruppo Italiano Trapianto Midollo 
Osseo) study confirmed the independent role of a first line 
CTAT on survival: in their study, half the patients who re-
ceived a first line CTAT still died from the infection (Gir-
menia et al., 2015b). 
Given the limited therapeutic options and the unsatis-
factory efficacy of the available treatments, prevention of 
KPC-Kp infection is the first provision to implement, fol-
lowed by screening for gut colonization and possibly gut 
decolonization, in order to reduce the risk of subsequent 
infections (Girmenia et al., 2015a).
It is important to remember that gut colonization rep-
resents the main source for KPC-Kp epidemic dissemina-
tion, that, in our experience, 100% of patients with KPC-
Kp infection were colonized earlier and that the rates of 
subsequent CRE infection in patients found to be colo-
nized by screening culture are 9% overall (Schechner et 
al., 2013), 27% among intensive care unit patients, 25.8% 
among autologous SCT patients and up to 39.2% among 
allogeneic SCT patients (Girmenia et al., 2015b).
In our experience, considering the small number of pa-
tients analyzed, the decontamination rate in the entire 
population was 71%, and 90% considering the patients 
receiving oral gentamicin only.
Despite the small number of patients analyzed in this 
study, our results are similar to others. Using an oral gen-
tamicin regimen of 80 mg four times daily, Zuckerman et 
al. reported decontamination of KPC-Kp in 66% hema-
tology patients without selection of gentamacin-resistant 
strains (Zuckerman et al., 2010). Tascini et al. reported a 
similar decontamination rate (68%) (Tascini et al., 2014) 
with a significant difference in decontamination rate be-
tween the group of patients receiving oral gentamicin only 
(96%) and the patients receiving oral gentamicin during 
CSAT (44%). According to our experience, this evidence 
suggests that the selective pressure of CSAT on gut micro-
biota may favor the persistent carriage of KPC-Kp, there-
by contributing to the higher failure rates observed versus 
monotherapy (Tascini et al., 2014).
One patient was treated with gentamicin although the 
KPC-Kp strain was highly resistant to gentamicin. Con-
sidering that resistant breakpoints are settled for blood 
concentration of gentamicin, one might hypothesize that 
gentamicin concentration in the feces might be higher 
than clinical breakpoint for bloodstream infection. This 
single case demonstrates that it is not advisable to sug-
gest gentamicin decontamination for gentamicin-resistant 
KPC-Kp strains.
Therefore, the selective oral decontamination therapy of 
KPC-Kp with oral gentamicin is safe and possibly effective 
and with this therapeutic option as a complementary ap-
proach for reducing the risk of severe infection with these 
notoriously difficult-to-treat MDR Enterobacteriaceae. 
The possible selection of gentamicin-resistant strains was 
negligible in our experience, because we stopped oral ther-
apy when it was not effective and we tried to avoid oral 
gentamicin with CSAT, a strong inducer of KPC-Kp gut 
colonization, and a cause of persistent gut colonization by 
KPC-Kp.
We are aware that hematologic patients are usually treat-
ed with CSAT for febrile neutropenia or for prophylaxis 
during neutropenia. On the other hand, colonization and 
subsequent infections caused by KPC-Kp have an extreme-
ly high rate of mortality, therefore a strategy to avoid CSAT 
should be adopted.
So far only 2 studies in the literature evaluating patients 
with HM treated with oral gentamicin, for a total of 55 
patients (Girmenia et al., 2015a; Machuca et al., 2016). 
Our experience adds another piece of information on the 
decontamination in these fragile patients. The concern 
over selecting gentamicin-resistant strains is probably 
overestimated and we might avoid selection of gentami-
cin resistance if we try to avoid CSAT and not prolong 
oral gentamicin therapy over 15 days if it is not effec-
tive. In our study we treated 2 patients for more than 15 
days, without successive induction of gentamicin-resis-
tant strains. The follow-up was only 90 days and in this 
kind of population and a longer period should be used in 
future experiences.
Avoiding colonization might be useful in hematological 
patients in order to shorten isolation procedures and 
leave available more beds in these units with limited re-
sources. In fact, other authors have already demonstrated 
that some patients that are super-spreaders of KPC-Kp, 
reducing the gut burden of KPC-Kp might be useful from 
an epidemiological point of view (Lerner et al., 2015).
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